Google Alert - Business

	Business Daily update ⋅ September 12, 2022
	NEWS
	Targeted Oncology Frontline Tislelizumab Shows Non-Inferior OS vs Sorafenib in Unresectable HCC Targeted Oncology At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma. Flag as irrelevant
	FierceHealthcare Envision Healthcare, UnitedHealth spar in dueling lawsuits FierceHealthcare UnitedHealthcare's war with physician staffing firms continues. Envision Healthcare filed suit against the insurer, the physician firm announced Friday, over claims denied by the country's largest health plan. UnitedHealthcare axed Envision from its ... Flag as irrelevant
See more results | Edit this alert

You have received this email because you have subscribed to Google Alerts. Unsubscribe | View all your alerts

Receive this alert as RSS feed

Send Feedback